PITX2, the novel biomarker to support breast cancer therapy selection

Discuss with us at AMP Europe 2018 how our new CE-IVD solution, the therascreen PITX2 RGQ PCR Kit, can help you better treat certain breast cancer patients

Evidence has accumulated that PITX2 (paired-like homeodomain transcription factor 2) gene methylation may serve as a novel predictive biomarker in certain high-risk breast cancer patients. For this patient group, including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients, current international guidelines recommend anthracycline-based chemotherapy as the standard-of-care, yet not all patients equally benefit from this treatment. To further improve therapy decision-making and to support physicians in giving patient advice, predictive biomarkers are of high importance.

QIAGEN’s therascreen PITX2 RGQ PCR Kit is a clinically validated CE-IVD DNA methylation assay which uses the percent methylation ratio (PMR) to predict patient response to anthracycline-based chemotherapy from formalin-fixed, paraffin-embedded patient samples. The result helps in selecting the most appropriate chemotherapy regimen for lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients.

The therascreen PITX2 RGQ PCR Kit provides clinically reliable determination of the PITX2 methylation ratio in lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patient tissue samples.

Register for a meeting on PITX2

 

The therascreen PITX2 RGQ PCR Kit is a CE-IVD kit for determination of the percent methylation ratio (PMR) in promoter 2 of the pituitary homeobox transcription factor 2 (PITX2) gene using methylation-specific real-time PCR on the Rotor-Gene Q 5-plex HRM instrument. The kit provides reagents optimized for reliable and sensitive determination of the PITX2 methylation status, and allows for a clinically validated determination of the PMR cut-off value of 12, which is predictive of patient response to anthracycline-based chemotherapy with or without endocrine therapy when used to test formalin-fixed, paraffin-embedded (FFPE) tissue samples from lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. The therascreen PITX2 RGQ PCR Kit is for in vitro diagnostic use, and is only available in Europe.

MerkenMerkenMerkenMerken

Visit us at AMP Europe 2018, booth #T19

Register for a demo
Social Sharing